ZIM
NBIX icon

Zacks Investment Management’s Neurocrine Biosciences NBIX Stock Holding History

Zacks Investment Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-51,176
Closed -$5.18M – 696
2023
Q1 		$5.18M Buy
51,176
+1,712
+3% +$178K 0.07% 187
2022
Q4 		$5.91M Buy
49,464
+1,091
+2% +$128K 0.08% 178
2022
Q3 		$5.14M Buy
+48,373
New +$4.91M 0.08% 171
2015
Q4 		– Sell
-7,969
Closed -$317K – 627
2015
Q3 		$317K Buy
+7,969
New +$385K 0.01% 500
2014
Q1 		– Sell
-27,084
Closed -$253K – 741
2013
Q4 		$253K Buy
+27,084
New +$264K 0.01% 602

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Zacks Investment Management's NBIX Position: Q2 2023 in Review

Zacks Investment Management sold out of Neurocrine Biosciences (NBIX) in Q2 2023, closing a stake of 51,176 shares — an estimated $5.18M sold.

Zacks Investment Management first reported a position in NBIX in Q4 2013 and held it in 5 quarters. The position peaked at $5.91M in Q4 2022. 456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • Zacks Investment Management reported no remaining Neurocrine Biosciences position as of Q2 2023 after selling out during the quarter.
  • Zacks Investment Management sold 51,176 Neurocrine Biosciences shares in Q2 2023, an estimated $5.18M.
  • Zacks Investment Management first reported a position in Neurocrine Biosciences in Q4 2013 and held it in 5 quarters.
  • Zacks Investment Management's Neurocrine Biosciences position peaked at $5.91M in Q4 2022.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on Zacks Investment Management's 13F filing for Q2 2023, filed 15 Aug 2023.